Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00074022
First received: December 10, 2003
Last updated: January 23, 2013
Last verified: January 2013

December 10, 2003
January 23, 2013
October 2003
November 2007   (final data collection date for primary outcome measure)
  • Number of patients experiencing dose limiting toxicities (DLTs), graded according to the National Cancer Institute Common Toxicity Criteria (NCI CTC) v2.0 (Phase I) [ Time Frame: Up to day 21 ] [ Designated as safety issue: Yes ]
  • Objective tumor response as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) (Phase II) [ Time Frame: Up to day 42 ] [ Designated as safety issue: No ]
    The 95% confidence intervals will be provided.
Not Provided
Complete list of historical versions of study NCT00074022 on ClinicalTrials.gov Archive Site
  • Stable disease rate [ Time Frame: Up to 6 weeks ] [ Designated as safety issue: No ]
  • Response duration [ Time Frame: Up to 4 years ] [ Designated as safety issue: No ]
    The 95% confidence intervals will be provided.
  • Toxicities of GTI-2040 combined with docetaxel, graded according to the NCI CTC v2.0 [ Time Frame: Up to 4 years ] [ Designated as safety issue: Yes ]
  • Time to disease progression [ Time Frame: Up to 4 years ] [ Designated as safety issue: No ]
  • Duration of stable disease [ Time Frame: Up to 6 weeks ] [ Designated as safety issue: No ]
  • Level of ribonucleotide reductase (RNR) activity [ Time Frame: Up to week 10 ] [ Designated as safety issue: No ]
    Logistic regression and descriptive statistics will be used.
  • Tumoral expression in terms of c-myc, R2 subunit protein levels and markers of proliferation (cyclin B1) and apoptosis (activated caspase 3) [ Time Frame: Up to week 10 ] [ Designated as safety issue: No ]
    Logistic regression and descriptive statistics will be used.
Not Provided
Not Provided
Not Provided
 
GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors
A Phase I/2 Study of GTI-2040 Combined With Docetaxel In Metastatic Or Unresectable Locally Advanced Non-Small Cell Lung Cancer

Phase I/II trial to study the effectiveness of combining GTI-2040 with docetaxel in treating patients who have recurrent, metastatic, or unresectable locally advanced non-small cell lung cancer, prostate cancer, or other solid tumors. GTI-2040 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. It may also increase the effectiveness of docetaxel by making the tumor cells more sensitive to the drug. Combining GTI-2040 with docetaxel may kill more tumor cells

OBJECTIVES:

I. Determine the recommended phase II dose of GTI-2040 and docetaxel in patients with recurrent, metastatic, or unresectable locally advanced non-small cell lung cancer, prostate cancer, or other solid tumors (phase I study closed to accrual as of 8/5/2004).

II. Determine the toxicity of this regimen in these patients. III. Determine the objective tumor response rate in patients treated with this regimen.

IV. Determine the stable disease rate, time to disease progression, objective response duration, and duration of stable disease in patients treated with this regimen.

V. Determine the pharmacokinetics of GTI-2040 when administered in combination with docetaxel in these patients.

VI. Correlate the pharmacokinetics of GTI-2040 with the biological and toxic effects of this regimen in these patients.

VII. Correlate baseline and post-treatment levels of ribonucleotide reductase activity in tumor biopsies and peripheral blood mononuclear cells and tumoral expression of c-myc, ras, pRAF1, pMAPK, and markers of apoptosis with clinical outcome in patients treated with this regimen.

OUTLINE: This is an open-label, dose-escalation, multicenter study.

Phase I (closed to accrual as of 8/5/2004): Patients receive GTI-2040 IV continuously on days 1-14. Patients also receive docetaxel IV over 1 hour on day 3 during course 1 and on day 1 for all subsequent courses. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of GTI-2040 and docetaxel until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. The recommended phase II dose (RP2D) is defined as the dose preceding the MTD.

Phase II: Patients receive GTI-2040 and docetaxel at the RP2D as in phase I.

Patients are followed every 3 months.

PROJECTED ACCRUAL: A total of 12-48 patients (12-18 for phase I [closed to accrual as of 8/5/2004] and 15-30 for phase II) will be accrued for this study within 4-16 months.

Interventional
Phase 1
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Recurrent Non-small Cell Lung Cancer
  • Recurrent Prostate Cancer
  • Stage III Prostate Cancer
  • Stage IIIA Non-small Cell Lung Cancer
  • Stage IIIB Non-small Cell Lung Cancer
  • Stage IV Non-small Cell Lung Cancer
  • Stage IV Prostate Cancer
  • Unspecified Adult Solid Tumor, Protocol Specific
  • Biological: GTI-2040
    Given IV
  • Drug: docetaxel
    Given IV
    Other Names:
    • RP 56976
    • Taxotere
    • TXT
  • Other: laboratory biomarker analysis
    Correlative studies
  • Other: pharmacological study
    Correlative studies
    Other Name: pharmacological studies
Experimental: Treatment (GTI-2040, docetaxel)

Phase I (closed to accrual as of 8/5/2004): Patients receive GTI-2040 IV continuously on days 1-14. Patients also receive docetaxel IV over 1 hour on day 3 during course 1 and on day 1 for all subsequent courses. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of GTI-2040 and docetaxel until the MTD is determined. The MTD is defined as the dose at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. The RP2D is defined as the dose preceding the MTD.

Phase II: Patients receive GTI-2040 and docetaxel at the RP2D as in phase I.

Interventions:
  • Biological: GTI-2040
  • Drug: docetaxel
  • Other: laboratory biomarker analysis
  • Other: pharmacological study
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
48
Not Provided
November 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histologically or cytologically confirmed diagnosis of 1 of the following:

    • Solid tumor malignancy (phase I only)*
    • Prostate cancer (phase I only)*
    • Non-small cell lung cancer (phase I and II)*
  • Recurrent, metastatic, locally advanced unresectable, or treatment-refractory disease
  • Measurable disease

    • At least 1 unidimensionally measurable lesion at least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan
    • Previously irradiated lesions are considered measurable provided they have demonstrated progression before study entry
    • No bone-only disease

      • Must have measurable disease other than bone lesions
  • No stage IIIA or IIIB non-small cell lung cancer without a malignant pleural or pericardial effusion that is eligible for first-line radical combined chemotherapy and radiotherapy
  • No known progressive or symptomatic brain metastases

    • Asymptomatic brain metastases allowed
  • Performance status - ECOG 0-2
  • Performance status - Karnofsky 60-100%
  • More than 3 months
  • WBC at least 3,000/mm^3
  • Absolute neutrophil count at least 1,500/mm^3
  • Platelet count at least 100,000/mm^3
  • No history of coagulopathy
  • Bilirubin no greater than 1.5 times upper limit of normal (ULN)
  • AST/ALT no greater than 2 times ULN (3.5 times ULN if liver metastases are present)
  • INR no greater than 1.3
  • APTT no greater than 1.25 times ULN
  • Creatinine no greater than 1.5 times ULN
  • Creatinine clearance at least 50 mL/min
  • No symptomatic congestive heart failure
  • No evidence of cardiac dysfunction
  • No unstable angina pectoris
  • No cardiac arrhythmia
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No active peptic ulcer disease
  • No poorly controlled diabetes mellitus
  • No pre-existing grade 2 or greater neuropathy
  • No ongoing or active infection
  • No contraindication to corticosteroids
  • No psychiatric illness or social situation that would limit compliance with study requirements
  • No prior allergic reaction attributed to compounds of similar chemical or biological composition to study drugs
  • No other concurrent uncontrolled illness
  • One, and only one, prior chemotherapy regimen for advanced disease (not including adjuvant therapy) allowed

    • Neoadjuvant/adjuvant chemotherapy allowed
  • More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas and mitomycin) and recovered
  • Prior multiple lines of endocrine therapy for advanced solid tumors allowed
  • More than 4 weeks since prior endocrine therapy and recovered
  • Concurrent steroids allowed
  • See Disease Characteristics
  • More than 4 weeks since prior radiotherapy and recovered
  • No concurrent radiotherapy to sole site of measurable disease
  • Prior surgery allowed
  • No concurrent anticoagulant therapy

    • Concurrent low-dose warfarin for central line thrombosis prophylaxis allowed
  • No concurrent combination antiretroviral therapy for HIV-positive patients
  • No other concurrent investigational or commercial agents or therapies intended to treat the malignancy
  • Concurrent bisphosphonates allowed
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT00074022
NCI-2012-02563, PMH-PHL-017, N01CM17107, CDR0000341677
Not Provided
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Not Provided
Principal Investigator: Natasha Leighl Princess Margaret Hospital Phase 2 Consortium
National Cancer Institute (NCI)
January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP